Wolfe Research Upgrades Sarepta to Outperform as DM1 and FSHD Catalysts Approach
With key MAD data for DM1 and FSHD siRNA programs expected in H2 2026, SRPT stock shows strong growth potential.
/ 185 items
#XY Analyst Up/Down↓
Raymond James Upgrades Tvardi Therapeutics to Outperform, Sets $10 Target on Strong TTI-109 Data
Tvardi’s new drug TTI-109 showed strong early results, fewer side effects, and potential in autoimmune diseases, boosting investor confidence.
Wall Street Boosts Compass Pathways as COMP360 Durability Data Strengthens Path to 2027 Approval
Positive six-month COMP360 results trigger analyst upgrades and higher price targets for Compass Pathways. Strong durability data clears path to potential 2027 FDA approval in treatment-resistant depression.
William Blair Initiates Outperform Coverage on Zura Bio, Citing Strong Potential for Tibulizumab
William Blair cites strong upside potential for lead candidate tibulizumab in hidradenitis suppurativa and systemic sclerosis.
Annovis Bio Gets Bullish Coverage from Roth Capital Amid Phase 3 Momentum
Annovis Bio receives bullish coverage from Roth Capital as its Phase 3 Alzheimer’s trial hits full enrollment.
Rodman & Renshaw Highlights (Z)-Endoxifen Potential as It Initiates Buy on Atossa Therapeutics
Rodman & Renshaw assigns Buy rating and $12 PT on (Z)-endoxifen, highlighting breast cancer program and rare disease upside.